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Inflammatory bowel disease (IBD) has been at-
tributed to overexuberant host immunity or the
emergence of harmful intestinal flora. The tran-
scription factor T-bet orchestrates inflamma-
tory genetic programs in both adaptive and
innate immunity. We describe a profound and
unexpected function for T-bet in influencing
the behavior of host inflammatory activity and
commensal bacteria. T-bet deficiency in the
innate immune system results in spontaneous
and communicable ulcerative colitis in the
absence of adaptive immunity and increased
susceptibility to colitis in immunologically intact
hosts. T-bet controls the response of the mu-
cosal immune system to commensal bacteria
by regulating TNF-a production in colonic den-
dritic cells, critical for colonic epithelial barrier
maintenance. Loss of T-bet influences bacterial
populations to become colitogenic, and this co-
litis is communicable to genetically intact hosts.
These findings reveal a novel function for T-bet
as a peacekeeper of host-commensal relation-
ships and provide new perspectives on the
pathophysiology of IBD.
INTRODUCTION
The intestinal lumen is massively colonized by bacteria,
and for most metazoans this relationship is beneficial(Ley et al., 2006). Prokaryotes partner with their eukaryotic
hosts to aid in the extraction of energy and nutrients from
food, and nonpathogenic bacteria suppress pathogenic
species (Backhed et al., 2005). An epithelial cell barrier
is essential for this symbiosis as it creates a boundary nec-
essary for coexistence by preventing mucosal inflamma-
tion in response to bacterial or other luminal stimuli (Mag-
alhaes et al., 2007). However, in some individuals this
balance is upset, resulting in persistent intestinal inflam-
mation that manifests as the two distinct clinical entities
of IBD, Crohn’s disease (CD) and ulcerative colitis (UC)
(Rakoff-Nahoum and Medzhitov, 2006). Determining the
factors that regulate these complex host-commensal rela-
tionships and promote the development of colitis is of
great clinical and scientific interest.
T-bet (Tbx21) is a T-box transcription factor family
member that regulates the differentiation and function of
immune system cells. Although initially described to direct
the development of a major subset of lymphocytes called
T helper 1 cells, recent work has firmly established T-bet
as a regulator of the type 1 proinflammatory immune re-
sponse in cells of both the adaptive and innate immune
systems (Glimcher, 2007). It has been implicated as a
key effector protein in autoimmune, allergic, and neo-
plastic diseases; nevertheless, its role in balancing im-
munity and autoimmunity is complex, and it is not well-
understood if T-bet protects against or promotes chronic
intestinal inflammation (Weigmann and Neurath, 2002).
Here we reveal an unexpected and powerful role for
T-bet in host-commensal interactions. Loss of T-bet in
mice lacking an adaptive immune system results in a spon-
taneous, highly penetrant, aggressive, and communicable
colitis that resembles human UC. Both the T-bet-deficient
genetic background and the microbiota its absenceCell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc. 33
engenders are required for disease initiation; but once
established, the microbiota from the afflicted mice is
vertically transmissible and causes intestinal inflammation
in wild-type (WT) mice. Thus we have identified a novel
function for T-bet in moderating host-commensal relation-
ships. This new mouse model of spontaneous UC pro-
vides exciting opportunities to further our understanding
of the etiology and pathogenesis of UC and interrogate
the complex nature of commensal microbial communities
and serves as a robust host for the evaluation of new
therapeutics.
RESULTS
T-bet Expression Protects against Colitis
and T-bet/ 3 RAG2/ Mice Develop
Spontaneous Colitis
The sulfated polysaccharide dextran sodium sulfate (DSS)
induces colitis via direct toxicity on mucosal epithelium.
T-bet/ mice developed more severe colitis upon DSS
administration than WT mice (Figures 1A and 1B), as
evidenced by a more extensive and severe inflammatory
infiltrate, containing neutrophils, mononuclear cells, and
more lymphoid aggregates, more edema, extensive ulcer-
ation, and crypt loss (Figure 1B). This observation was
unexpected as DSS colitis arises from overabundant
type 1 cytokines, IFNg, IL-12, IL-1, and TNF-a. T-bet/
T cells produce a type 2 cytokine profile that is protective
for most T cell-driven colitis models. Indeed, T-bet defi-
ciency is protective against the T cell adoptive transfer
SCID colitis model (Neurath et al., 2002). To clarify whether
T-bet’s protective function resided in innate immunity,
we examined T-bet/ mice bred onto the RAG2/ back-
ground. A comparative survey of the gastrointestinal (GI)
tracts of T-bet/ 3 RAG2/, RAG2/, T-bet/, and
WT mice in our colony revealed that T-bet/ 3 RAG2/
mice spontaneously developed a highly penetrant and
severe colitis (Figures 1C and 1D). This colitis was appar-
ent by 4 weeks of age and increased in severity over time
(Figure 1E). Of note, our mice are housed in a barrier facility,
documented to be free of known colitogenic pathogens
such as Helicobacter hepaticus, bilis, and muridarum.
Spontaneous Colitis in TRUC Mice Phenocopies
Human UC and Is Characterized by an Early
Colonic Epithelial Barrier Breach
T-bet/3RAG2/ (herein referred to as TRUC [T-bet/
x RAG/ ulcerative colitis]) mice develop colitis that
bears a striking resemblance to human UC (Figure 2A),
notable for anorectal prolapse (Figure 2A1), from rectal
inflammation. TRUC colons demonstrated continuous
inflammation of the rectum and left colon by 4 weeks of
age (Figure 2A2b), and by 8 weeks, there was marked in-
flammation and colonic thickening (Figure 2A2d) not seen
inRAG2/ controls (Figure 2A2c). Microscopically, TRUC
colitis phenocopies many aspects of human UC (Fig-
ure 2A4) with a mixed inflammatory infiltrate in the lamina
propria containing both mononuclear and polymorphonu-34 Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc.clear cells, neutrophil infiltration of the crypt and surface
epithelium, and epithelial injury with surface denudations
and ulcerations associated with crypt loss and epithelial
mucodepletion. The stomach and small intestine ap-
peared microscopically normal, similar to UC but in con-
trast with CD and most spontaneous mouse models of
colitis. Examination of mice from one week postnatally
revealed no evidence of colitis until 4 weeks (Figure 1E).
However, intrarectal instillation of fluorescently labeled
dextran, to test the integrity of the colonic epithelial barrier
in 3.5-week-old mice (Karhausen et al., 2004), demon-
strated significantly increased permeability in TRUC com-
pared to RAG2/ and T-bet/ mice (Figure 2B) with
2-fold higher serum fluorescence (p = .0002 TRUC ver-
sus RAG2/). Colonic permeability increased with age,
with a 3-fold increase between 4 and 5 weeks and an
8.6-fold increase between 5 and 6 weeks (p = .00036)
(Figure 2C). Hence, a decrease in colonic epithelial integ-
rity precedes histologically detectable colitis and worsens
with progression.
Although abnormal tight junctions may contribute to IBD
pathogenesis (Bruewer et al., 2006), EM (electron micro-
graphs) of TRUC and control colonic mucosa from mice
aged 2–12 weeks showed intact epithelial tight junctions
(Figure 2D: 2 weeks [panel 1], 3 weeks [panel 2], and 4
weeks [panel 3]). However, numerous large epithelial
discontinuities were observable on EM by 3.5 weeks of
age (Figures 2E1–2E4), which likely accounted for the
increased permeability. Further, the degree of cell death
was well above the intrinsic rate of epithelial turnover.
We quantified colonic epithelial apoptosis by TUNEL (ter-
minal transferase dUTP nick end labeling) in 5-week-old
mice when significant colonic permeability exists (Fig-
ure 2C). While TUNEL+ cells were noted at the top of
crypts in all genotypes, TUNEL+ cells were distributed
throughout the crypt in TRUC mice, and in many cases
the entire crypt consisted of TUNEL+ cells (Figure 2F).
Quantitation of TUNEL+ cells/100 crypts for all 4 geno-
types showed a 4- to 5-fold increase in TUNEL+ cells
in TRUC mice (Figure 2G), accentuated if TUNEL+ cells/
epithelial cells/crypt is plotted (Figure S1B).
TNF-a Drives Tissue Injury in TRUC Colitis and
TNF-a Overproduction Maps to Colonic DCs
We analyzed the TRUC versus RAG2/ colonic cytokine
milieu in colon explant cultures. TNF-a was significantly
elevated in TRUC explant cultures at 4 weeks and in-
creased over time (Figure 3A). There were no marked dif-
ferences in the levels of other IBD-associated cytokines,
IFNg, IL-1a, IL-1b, IL-6, IL-10, IL-12, IL-13, or IL-23 at 4
weeks (Figure 3B). TNF-a is a key effector cytokine in
IBD thought to lead to an increased inflammatory tone of
the intestinal epithelium. TNF-a neutralizing Ab therapy
is widely used in IBD treatment. Anti-TNF-a Ab therapy
suppressed TRUC colitis as evidenced by colon weight
(Figure S1A) and colitis score (Figure 3C). The microscopic
appearance of TNF-a Ab-treated TRUC colons was
indistinguishable from that of control mice. Of interest,
Figure 1. T-bet Expression Protects against Colitis and T-bet/ 3 RAG2/ Mice Develop Spontaneous Colitis
(A) WT and T-bet/ mice, age 8 weeks, treated with 4% DSS for 8 days. One representative experiment of three, n = 8 per group, p = .0031.
(B) Photomicrographs of DSS-treated WT (upper panel) and T-bet/ (lower panel) colons.
(C) TRUC mice develop a spontaneous, highly penetrant colitis. Colitis score for each mouse denoted by a dot, the mean for each group shown as
a horizontal bar. n = 7 per group, all 12 weeks old.
(D) Mean colon weights (mg) for the mice in (C). Error bars denote standard deviation (SD).
(E) TRUC colitis severity increases with time. Mean colitis score ± SD (denoted by error bars), n = 10 per group, except for 1-week-old group, n = 8.anti-TNF-a treatment decreased the number of apoptotic
epithelial cells to normal levels in mice treated from 4–8
weeks of age (Figure 3D).
TNF-a could modulate either pro-survival or pro-death
signaling pathways in cells. We examined the effects of
TNF-a on the apoptosis of colonic epithelial cells (CECs),
isolated from RAG2/ and TRUC colons cultured with or
without TNF-a. After 6 days, the untreated RAG2/ and
TRUC CECs had quite similar percentages (%) of apopto-
sis (14.2% versus 14.0%: RAG2/ versus TRUC); how-
ever, TNF-a-treated cells displayed a marked difference
in apoptosis (13.7% versus 53.8%: RAG2/ versusTRUC) (Figure 3E). Since CECs do not express T-bet, their
exposure to the TRUC colonic environment likely sensi-
tized them to the effects of TNF-a. Cell surface TNFR1
does differ between TRUC and RAG2/ CECs even from
2-week-old mice (data not shown). To discern whether
CEC death is a direct or indirect effect of TNF-a, we gener-
ated TRUC mice that were also deficient in TNF-a receptor
by crossing them onto TNFR1/p55/ mice. Eight-week-
old triple-deficient mice showed no evidence of colitis,
suggesting that TNF-a signaling through TNFR1/p55 is
a central event in disease pathophysiology (Figure 3F).
These experiments established the centrality of TNF-a inCell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc. 35
Figure 2. Spontaneous Colitis in TRUC Mice Phenocopies Human UC and Is Characterized by a Colonic Epithelial Barrier Breach
(A) (1) TRUC mouse (8 weeks) with anorectal prolapse. (2) Photograph of distal colons of RAG2/ mice at 4 weeks (a) and 8 weeks (c) and of TRUC
distal colons at 4 weeks (b) and 8 weeks (d) (anorectal junction at bottom). Vertical bar delineates the inflamed, thickened colonic wall. Colonic wall
thickening with prolapsed rectal mucosa in 8-week-old TRUC mice. (3) Normal colonic mucosa in 6-week-old RAG2/ mouse, 1003. (4) Represen-
tative disease in 6-week-old TRUC mice. Note mucosal thickening, surface ulceration, crypt distortion and hyperplasia, and dense mixed inflamma-
tory cell infiltrate in the lamina propria (compare to panel 3), 1003.
(B)Intrarectal FITC-dextran was administered to 3.5 week T-bet/, RAG2/, and TRUC. Serum fluorescence measured at the indicated time points.
One representative experiment of three, n = 4–6 per group (p = .0002, 60 min TRUC versus RAG2/).36 Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc.
this model and led to the question of what cell type(s) was
responsible for TNF-a production in the colon.
We performed intracellular cytokine analysis on cells
isolated from TRUC and RAG2/ colons. Leukocyte
(CD45+) populations had higher staining for TNF-a than
epithelial and other nonleukocyte cells (Figure 3G). Among
the leukocyte subsets, there was no observable staining
for NK cells by flow cytometry (FC) or IHC in TRUC colons
(data not shown). TNF-a in macrophages, granulocytes,
and neutrophils could not account for the levels of TNF-
a observed (Figure 3G). However, there was significant
accumulation of TNF-a in TRUC colonic DCs (Figure 3G),
suggesting that colonic DCs are the principal TNF-a-
producing cell type. A time course of TNF-a production
of TRUC and RAG2/ colonic DCs from mice aged 2–8
weeks (Figure 3H) showed increased TNFa as early as
2 weeks of age, prior to any observed epithelial disconti-
nuities by microscopy. Thus overproduction of TNF-a by
colonic DCs precedes the development of epithelial
barrier abnormalities and colitis.
T-bet Regulates Production of TNF-a in DCs
To determine if T-bet was expressed in colonic DCs as in
DCs in the peripheral lymphoid system, RAG2/ colons
were stained with CD11c to identify DCs and adjacent se-
rial sections were stained for T-bet (Figures 4A1 and 4A2).
While the required serial sectioning prevents precise
colocalization, there were many T-bet+ cells in areas of
dense CD11c staining. We confirmed this finding by stain-
ing FACS-isolated colonic DCs from RAG2/ mice with
a-T-bet Ab and DAPI. T-bet staining (red) is evident, and
there is colocalization with the DAPI (blue) stain in the
nucleus (Figure 4A3).
We next examined T-bet expression in human colonic
biopsies. Specimens were stained with S100 (DCs red)
and T-bet (brown). A representative DC with T-bet staining
is shown (Figure 5A4). Demonstration of T-bet expression
in human colonic DCs is a novel observation as T-bet
expression had only previously been demonstrated in hu-
man colonic T cells (Neurath et al., 2002). There was no T-
bet expression in CECs (Figure 4A2) by IHC nor has T-bet
been detectable in CEC lysates (data not shown). T-bet is
expressed in both mouse and human colonic DCs.
To explore T-bet’s role in DC TNF-a production, we
used mouse bone marrow DCs (BMDCs) as colonic DC
yields are insufficient for biochemical evaluation. LPS
matured T-bet/ BMDCs, similar to colonic DCs, over-
produce TNF-a compared to WT BMDCs (Figure 4B).
The observations that loss of T-bet expression in colonicand BMDCs results in increased TNF-a production sug-
gested that T-bet may directly regulate TNF-a in DCs.
Chromatin immunoprecipitation (ChIP) and quantitative
real timer PCR (qPCR) (Figure 4C) assays revealed that
T-bet bound the mouse TNF-a promoter at two T-box
consensus sites at approximately 1200 and 500 rela-
tive to the transcription start site (TSS) but not at regions
examined upstream of 1200 (data not shown), with
T-bet/ BMDCs and preimmune sera as controls. We
also performed ChIP assays in human myeloid DCs.
Although there is little sequence homology between the
50 UTR of the mouse and human TNF-a promoters and
T-box consensus sites can be rather degenerate, T-bet
bound the human TNF-a promoter as demonstrated by
ChIP and qPCR (Figure 4D) at approximately400 relative
to the TSS and did not bind more upstream.
To investigate whether T-bet is a negative regulator of
TNF-a transcription as would be predicted from the TNF-
a overproduction phenotype of T-bet/ DCs, RAW cells
were cotransfected with a TNF-a promoter luciferase con-
struct, a constitutively active Ikkb mutant to activate TNF-
a transcription, and T-bet. Transfection withT-bet reduced
NFkB-driven TNF-a promoter activity in RAW cells in
a dose-dependent fashion, suggesting that T-bet functions
as a negative regulator of TNF-a transcription (Figure 4E).
CD4+CD25+ T-Regulatory Cells Control
TRUC Colitis
T-bet/ immunosufficient mice do not develop spontane-
ous colitis although they display increased susceptibility
to DSS and have been shown to have increased suscep-
tibility to oxazolone-induced colitis, a Th2 model of colitis
(Neurath et al., 2002). T-bet/ and WT mice possess an
adaptive immune system as do most IBD patients. To
test the hypothesis that a component of the adaptive
immune system might act as a repressor of colitis in immu-
nosufficient hosts, we performed adoptive transfer (AT)
experiments in TRUC. As evidenced by colitis scores,
the protection we observed could not be attributed to con-
ventional T helper or B cells because transfer of naive CD4
T cells (T-bet/ or WT) or B cells did not protect against
disease (Figure 5A). The CD4 T-regulatory cell (T-reg) is
a potent repressor of effector T cell function that might
have prevented the development of colitis in the T-bet/
host. AT of T-regs reverses intestinal inflammation in
H. hepaticus-infected RAG2/ mice, an innate immune-
driven colitis model (Maloy et al., 2005). AT of either WT
or T-bet/ T-regs controlled TRUC colitis (Figure 5B). Co-
lons from mice infused with T-regs were free of any signs(C) Intrarectal FITC-dextran administered to TRUC at 4, 5, and 6 weeks. Serum fluorescence at the indicated time points (p = .0036, 60 min 6 versus
5 weeks). One representative experiment of three, n = 5 per group. Error bars denote SD.
(D) TRUC colonic tight junctions surveyed by EM: representative images prior to 2 weeks (1), 3 weeks (2), and 4 weeks (3), 25,0003.
(E) Colonic epithelial discontinuities present in 3.5 week TRUC. Representative EM images, (1) 8003, (2) 15003, (3) 10003, (4) 30003.
(F) Increased apoptosis in TRUC colonic epithelium. WT, T-bet/, RAG2/, and TRUC colonic epithelium at 5 weeks stained with DAPI (blue) and
TUNEL (green), 2003.
(G) Epithelial crypt and TUNEL+ cell counts. Five slides generated from each genotype group (2–3 mice per genotype). Five hundred crypts per
genotype were scored. Where shown, error bars denote SD.Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc. 37
Figure 3. TNF-a Drives Tissue Injury in TRUC Colitis and TNF-a Overproduction Maps to Colonic DCs
(A) TNF-aELISAs on colon explant cultures from 4-, 8-, and 12-week-old TRUC (open) andRAG2/ (shaded). One representative experiment of three
is shown; samples pooled, n = 4 per group.
(B) IL-23, IL-13, IL-12p40, IL-10, IL-6, IL-1a, IL-1b, and IFNg levels of colon explant cultures from TRUC (open) and RAG2/ (shaded); samples
pooled, n = 4 per group. Data represent the mean of three independent experiments, error bars denote SD.
(C) 4 week TRUC were treated with anti-TNF-a Ab or an isotype control for 4 weeks. Colitis scores for treated versus control, p = .0023. One repre-
sentative experiment of three is shown, n = 4 per group.
(D) Apoptotic (TUNEL+) epithelial cells counts; anti-TNF-a versus control, p = .0016.
(E) TUNEL staining of cultured TRUC colonic epithelial cells (CD45 cytokeratin 5/8+) treated with TNF-a compared to TNF-a treatedRAG2/ colonic
epithelial cells (53.8% versus 13.7%). One representative experiment of four is shown.
(F) Colitis scores for 8-week-old TRUC TNFR1/p55/ and TRUC mice, p < .0001. Colonic cell suspensions were stained with Abs directed against
cell-surface markers and permeabilized to allow for detection of intracytoplasmic TNF-a by flow cytometry.
(G) TNF-a production by immunocytes (CD45+). RAG2/ cells as controls. Abs against Gr-1, F4/80, and CD11c paired with class II were used to
identify the immunocytes with the highest TNF-a production.
(H) Colonic DC production of TNF-a during the disease course, 2–8 weeks. The mean and SD of three independent experiments are plotted. Vertical
bars denote the right-sided tail of the isotype control staining. Data are representative of three independent experiments; samples were pooled,
n = 10–20 per group. Where shown, error bars denote SD.of colitis. Imaging TRUC colons to document that the
transferred cells had trafficked to the colon using CD3
staining revealed that the CD3+ cells were in close contact38 Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc.with DCs as shown by costaining with CD11c (Figure
5C), suggesting that crosstalk between T-regs and DCs
may suppress the T-bet-deficient DC proinflammatory
Figure 4. T-bet Regulates Production of
TNF-a in DCs
(A) T-bet is expressed in colonic DCs. (1)
CD11c staining of RAG2/ colonic mucosa,
2003. (2) Serial section of (1) stained with
anti-T-bet Ab, 4B10, 2003. (3) Sorted colonic
mouse DC stained with anti-T-bet Ab (red)
and DAPI (blue), 10003. (4) Human colonic
DC, S100 (pink), anti-T-bet (brown), 10003.
(B) Loss of T-bet expression in BMDCs results
in increased production of TNF-a.
T-bet binds the TNF-a promoter.
(C) qPCR of mouse bone BMDCs ChIP sam-
ples. Primer sets A and B, approximately 500
and 1200 bp upstream of the TSS. A schema
of the promoter showing T-box consensus
sites and the location of primers used. Data
are the mean of three experiments.
(D) qPCR of human myeloid DC ChIP samples,
one representative experiment of three.
(E) T-bet negatively regulates TNF-a gene tran-
scription. RAW cells transiently cotransfected
with a 3 kb TNF-a promoter luciferase con-
struct, a constitutively active Ikkb mutant con-
struct to activate TNF-a transcription, a Renilla
construct for normalization of transfection effi-
ciency, and varying concentrations of a full-
length T-bet cDNA construct or control plas-
mid. TNF-a promoter activity is shown as
a function of relative luciferase activity. Data
are representative of three independent exper-
iments. Where shown, error bars denote SD.phenotype. Colon explant cultures from TRUC mice
injected with T-regs 4 weeks earlier showed markedly
reduced TNF-a levels similar to control RAG/ colonic
explants (Figure 5D). We hypothesized that colonic DC
T-bet deficiency might confer a genetic susceptibility to
aberrant TNF-a inflammatory responses to the microbial
environment.
The TRUC Colonic Environment Is a Niche
Supporting a Colitogenic Microbial Community
Whose Suppression Prevents Colitis across
Generations
The colonic luminal contents are abundant in microbiota
(Hooper and Gordon, 2001), and intestinal DCs constantly
sample these microbes (Chieppa et al., 2006; Niess and
Reinecker, 2006). Most mouse models of colitis are mi-
crobe dependent, and patients with IBD often have favor-
able if not durable responses to antibiotic therapy. Todetermine if TRUC colitis was driven by the gut microbiota,
mice were treated with broad spectrum antibiotics: vanco-
mycin (V), metronidazole (M), neomycin (N), and ampicillin
(A)—a combination previously shown to deplete enteric
microbial communities (Fagarasan et al., 2002; Rakoff-
Nahoum et al., 2004). Treatment with the VMNA combina-
tion cured the mice of their colitis, and selective treatment
with metronidazole alone cured the colitis as well, as dem-
onstrated by colitis scores (Figure 6A). Conventional cul-
turing of fecal pellets from VMNA antibiotic-treated and
control mice demonstrated relatively unchanged aerobic
colony counts (1010.11 versus 1010.16), but anaerobic colony
counts were dramatically decreased (109.74 versus <104.01;
log10CFU/gram dry weight of stool). Treatment for several
months induced not only a 100,000-fold decrease in the
culturable fecal anaerobes but also remission in all treated
TRUC mice. These two observations drew attention to the
potential pathogenicity of TRUC anaerobic commensals.Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc. 39
Figure 5. CD4+CD25+ T-Regulatory Cells Control TRUC
(A) Four week TRUC injected with PBS, 13 106 B cells, or 13 106 naive T cells, WT or T-bet/. Colitis scores at 2 weeks post-injection. Represen-
tative data from one of three experiments, n = 4 per group.
(B) Four week TRUC mice injected with 75,000 T-regs (CD4+CD25+CD62L+), WT or T-bet/, or PBS. Colitis scores at 4 weeks post-injection. One
representative experiment of three is shown, n = 6–8 per group.
(C) Photomicrograph of TRUC colon (T-reg treated). T-regs (CD3, green) and DCs (CD11c, red), 4003.
(D) Adoptive transfer of T-regs normalizes TRUC TNF-a levels. Four week TRUC injected with 75,000 T-regs (CD4+CD25+CD62L+) or PBS. TNF-a
levels from colon explant cultures 4 weeks post-injection, RAG2/ colon explants as a control. Samples pooled, n = 4–5 per group. Where shown,
error bars denote SD.We questioned the origin of the pathogenic TRUC mi-
crobial community. Did pathogenic anaerobic commen-
sals expand anew at each generation in response to the
developing TRUC colonic niche, or were colitogenic mi-
crobes propagated transgenerationally from founder
TRUC mice? Genetic susceptibilities are heritable and
microbial communities are also ‘‘heritable,’’ as they are
passed from parent to offspring (Tannock, 2006). We
asked whether the TRUC colitogenic microbial community
was vertically transmissible. TRUC colitis is highly pene-
trant and develops at a young age. TRUC progeny had co-
litis, raising the issue of whether the progeny of antibiotic-
treated (Abx) TRUC mice would develop colitis. We bred
Abx mice and examined their progeny, who had no ex-
posure to antibiotics after weaning, after they matured
to adulthood. The progeny had no evidence of colitis
(Figure 6B). Thus, in TRUC mice, such treatment cures
them of disease and prevents their progeny from develop-
ing colitis into adulthood. These experiments interested us
in the communicability of TRUC colitis.
TRUC Colitis Is Communicable to T-bet-Sufficient
Mice
We performed crossfostering experiments to determine if
TRUC intestines possessed a microbial community that
was colitogenic in T-bet sufficient mice. We provided40 Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc.a mother different from the birth mother at the day of birth
to RAG2/ and WT mice and assessed the development
of colitis in these crossfostered (X-F) progeny. Adult
RAG2/ and WT mice X-F by TRUC mothers developed
colitis that was histologically similar to TRUC (Figures 6C
and 6D). Colitis scores from conventionally reared
RAG2/ and WT mice are shown for comparison. The co-
litis of X-FRAG2/ mice was more severe than that of X-F
WT. Hence, genetically ‘‘resistant’’ strains can vertically
acquire colitis from association with the pathogenic
microbiota of affected mice.
The vertical transmission of TRUC colitis raised the issue
of whether TRUC colitis is horizontally transmissible. Per-
haps colitis transmission could only occur in the neonatal
period at a time when the immune system is immature, or
perhaps transmission required maternally transmitted
factors such as breast milk in addition to commensal mi-
crobiota. To test these possibilities, adult RAG2/ mice
were co-housed at a 1:3 ratio with age- and sex-matched
adult TRUC mice for 8 weeks. Remarkably, both RAG2/
and WT co-housed mice had evidence of colitis with ele-
vated colitis scores, demonstrating that TRUC colitis is
horizontally transmissible. These results suggest that not
only is TRUC colitis communicable but also that the T-
bet-deficient mucosal innate immune system creates
a niche for a colitogenic microbial community. The
Figure 6. The TRUC Niche Generates a Colitogenic Microbial Community that Is Transmissible to T-bet-Sufficient Mice
(A) Colitis scores for 6-week-old TRUC mice treated with vancomycin (V), metronidazole (M), neomycin (N), and ampicillin (A) or metronidazole (M)
alone for 6 weeks. One representative experiment of three, n = 4 per group.
(B) Colitis scores for adult progeny of antibiotic-treated mice. Three separate litters are shown for antibiotic-treated breeders and 1 litter is shown from
untreated breeders, p < .0001.
Communicability of TRUC colitis. Colitis scores for crossfostered RAG2/ mice (C) and WT mice (D). Mice are from three experiments (TRUC and
RAG2/) and two experiments (TRUC and WT). RAG2/ reared by RAG2/ female and WT reared by WT female shown for comparison.
(E) TNF-a ELISA on colon explant cultures: RAG2/ crossfostered by TRUC, TRUC reared by TRUC, RAG2/ reared by RAG2/, TRUC TNFR1/
fostered by TRUC, and TRUC TNFR1/ reared by TRUC TNFR1/. Samples were pooled, n = 4–8 per group.
(F) Colitis scores for RAG2/ and WT co-housed with TRUC for 8 weeks. RAG2/ and WT co-housed with genotype-identical mice shown for
comparison. Horizontal bars represent the mean. Where shown, error bars denote SD.following question remained: Was the colitis contracted by
T-bet-sufficient mice characterized by the high levels of
TNF-a that are central to the pathophysiology of TRUC co-
litis and originate from T-bet deficiency in DCs. Perhaps
the transmitted colitogenic microbial community acted
via a different mechanism to induce colitis in T-bet-suf-
ficient hosts. RAG2/ and TRUC TNFR1/ mice were
fostered by TRUC mice and then explant cultures were
performed on X-F and control mice. As expected, the
RAG2/ X-F mice displayed evidence of colitis. TNF-
a levels were not elevated in TRUC X-F RAG2/ orTRUC TNFR1/ explant cultures (Figure 6F). TRUC mice
harbor microbiota that drive a TNF-a-mediated colitis in
the absence of T-bet yet induce an etiologically distinct
colitis in T-bet-sufficient mice.
DISCUSSION
Our results reveal an unexpected role for the transcription
factor T-bet in maintaining host-commensal relationships
in the GI tract. T-bet fosters harmony between colonic eu-
karyotes and prokaryotes by establishing in the immuneCell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc. 41
system genetic programs that affect the behavior of the
colonic epithelium. T-bet functions in DCs to avoid proin-
flammatory responses to commensal microorganisms by
regulating TNF-a production to ensure the integrity of
the epithelial barrier. From the perspective of the microbial
communities inhabiting the colon, the TRUC colonic envi-
ronment facilitates the growth of a collection of colitogenic
bacteria. Once generated, this community of bacteria
drives intestinal inflammation even in immunosufficient
mice that express T-bet.
The pathophysiology of IBD has been attributed to
mucosal immune system dysregulation or gut microbiota
and/or abnormal epithelial barrier function (Strober
et al., 2007). Deletion of IKKb or NEMO, solely in intestinal
epithelium, for example, results in spontaneous colitis
(Nenci et al., 2007; Zaph et al., 2007). The characteristics
of TRUC colitis described here suggest a link between
these two seemingly disparate mechanisms since T-bet
expression impacts both the host’s mucosal immune sys-
tem and barrier function as well as the commensal micro-
bial community.
T-bet and the Cytokine Milieu
An altered mucosal cytokine milieu drives inflammation in
both UC and CD (Bouma and Strober, 2003). We show
that TNF-a is selectively elevated prior to and at the onset
of pathologically diagnosable disease, and treatment
starting at 2 weeks of age, prior to observable disease,
and treatment at 8 weeks of age, in the setting of fulminant
disease, are both therapeutic (Figures S1B and S1C).
Taken together, our studies have firmly established TNF-
a as a key initiating cytokine in our model.
Neutralizing TNF-a Ab may act by binding TNF-a in the
serum, sequestering it and preventing it from binding its re-
ceptor, or by binding cell-surface-associated TNF-a to in-
duce signaling events resulting in apoptosis of TNF-a-pro-
ducing cells (Shen et al., 2006). Colonic DCs appear to
produce the bulk of TNF-a in the TRUC colon, but intestinal
epithelial cells and colonic myofibroblasts also produce
TNF-a (Lan et al., 2005; Rogler et al., 2001). Analysis of
small intestinal biopsies from CD patients suggests that
an imbalance in intestinal DC populations may initiate
and perpetuate inflammation (Silva et al., 2004). How
mucosal DCs decode environmental signals to mount ap-
propriate immune responses is of great interest as its dys-
regulation is clearly a driving force in TRUC and in human
IBD (Iwasaki, 2007).
Anti-TNF-treated TRUC colons were indistinguishable
from controls, with no evident DC accumulation consis-
tent with the notion that anti-TNF-a therapy induces apo-
ptosis of TNF-a-producing cells in colitis. Our experiments
also address a causality dilemma in the IBD field: that is,
whether the epithelial barrier breach or the aberrant in-
flammation is the initial pathologic event. Elevated TNF-a
in TRUC colonic DCs preceded remarkable epithelial
discontinuities, and antibiotic treatment reduced TNF-a
concentrations in colon explant cultures. Thus, we favor
the idea that bacterially driven production of TNF-a from42 Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc.colonic DCs is an early, initiating event that triggers break-
down of the intestinal epithelium with consequent ongoing
influx of pathogenic microbiota resulting in chronic inflam-
mation. TNF-a blockade is an important therapeutic mo-
dality to treat IBD but, as with many biologics, has limiting
toxicities. Local augmentation of T-bet activity in intestinal
mucosal DCs may be an alternative approach to regulat-
ing TNF-a production.
TRUC Transmissibility
TRUC colitis is both vertically and horizontally transmissi-
ble to T-bet-sufficient mice, although the penetrance and
severity of horizontally transmitted TRUC colitis was re-
duced relative to vertically transmitted colitis. Cellular, cy-
tokine, or growth factor differences in TRUC milk may con-
tribute to TRUC colitis, but additional factors, aside from
the absence of potentially inflammatory breast milk, may
be involved. Bacterial colonization of mice and humans
starts in the birth canal and continues after parturition.
The adult mice used in the co-housing experiments
have well-established microbial communities that may
hinder the influx of colitogenic microbiota. Also, effective
horizontal transmission depends on the coprophagic
and grooming behaviors of individual mice and can vary
greatly. The transmissibility experiments suggest that
TRUC colitis is not only a microbially driven disease but
also that colitogenic microbes have the ability to drive dis-
tinct colitides dependent upon different immunological
mechanisms based on host genotype.
T-bet and the Microbial Flora
TRUC colitis is microbe dependent and transmissible.
Conventional culture data from antibiotic-treated versus
untreated TRUC mice suggest that a set of anaerobic
microbes may be pathogenic. We were unable to detect
Helicobacter hepaticus, bilis, ormuridarum by PCR-based
methods, and there were no marked differences in the cul-
turable anaerobes, including Enterococcus and Prevotella
species, or aerobes from fecal pellets from WT, T-bet/,
RAG2/, and TRUC mice (data not shown); however,
standard culturing techniques are capable of identifying
only a small fraction of the known anaerobic microbiota.
Genomic approaches using 16S rDNA enumerations are
underway to identify this novel collection of colitogenic
bacteria.
A genomic survey of mouse intestinal microbiota
showed an anaerobic expansion of the microbiota in
RAG2/ mice (Suzuki et al., 2004). Deficiency of both
T-bet and RAG2 may result in microbial population shifts
such that a host is exposed to an excessive dose of proin-
flammatory commensals and/or an insufficient dose of
protective commensals. The crossfostering experiments
suggest that T-bet deficiency influences the nature of
microbial communities resulting in a niche favorable for a
colitogenic microbial population. These colitogenic bac-
teria can be transmitted regardless of the genotype of
the recipient. Hence, T-bet-sufficient pups fostered by
a TRUC mother develop the disease. We envision the
colitogenic process as instigated by T-bet deficiency but,
once established, perpetuated independently of T-bet.
The molecular link between T-bet genetic programs en-
forced in the gut and the generation of colitogenic bacteria
remains unclear. Intriguingly, vertically transmitted colitis
is not characterized by high levels of TNF-a, suggesting
that other colitogenic mediators, perhaps IL-23 or IL-17,
can be evoked by the transfer of colitogenic bacteria.
Identification of the colitogenic bacteria present in these
T-bet-sufficient fostered pups should provide insight into
microbial origins of mechanistically distinct colitides.
Control of T-bet-Initiated Colitis by
T-Regulatory Cells
The difference in severity of TRUC X-F WT and RAG2/
colitis mice coupled with the observation that immunosuf-
ficient T-bet/ mice do not develop spontaneous colitis
led to experiments demonstrating that T-regs prevented
the development of colitis in T-bet/ mice. The biology
of T-regs and their contribution to promoting tolerance
and preventing autoimmunity has burgeoned recently
(Fontenot and Rudensky, 2005) with demonstrations that
T-regs can downregulate innate immunity-driven inflam-
mation in both the H. hepaticus RAG2 infection model
and the SCID T cell adoptive transfer model (Maloy
et al., 2005; Uhlig et al., 2006). We found that infusion of
T-regs was an effective treatment for TRUC colitis. Follow-
ing T-reg transfer, we observed DCs in close contact with
T-regs in the colon as described in NOD pancreatic LN
(Tang et al., 2006). Clinical trials involving T-reg transfer
for IBD patients are underway. Here we provide compel-
ling evidence for an important role of T-regs in a novel
model of innate-immune system-driven UC.
TRUC colitis mirrors much of the complexity of human
UC. This colitis involves mucosal innate immune cell dys-
regulation, cytokine-driven inflammation, epithelial barrier
breach, and pathogenic commensal microbial communi-
ties and invokes a role of T-regs in the maintenance of in-
nate immune cell homeostasis in the enteric immune sys-
tem. Our experiments suggest that there may be a window
of vulnerability in early life that confers susceptibility to
development of colitis. The TRUC model provides oppor-
tunities to study the pathogenesis of this inflammatory
disease and more broadly to understand the biological
programs that balance host-commensal relations at mu-
cosal surfaces. T-bet is not only a key regulator of type 1
immune responses but also a peacekeeper at the prokary-
otic-eukaryotic interface.
EXPERIMENTAL PROCEDURES
Animal Husbandry
Mice were housed in microisolator cages in a barrier facility and stud-
ied according to institutional and NIH guidelines. All mice used were
specific pathogen free and negative for Helicobacter hepaticus, bilis,
and muridarum. We thank Drs. K. Malloy (Oxford University) and T.
Yatsunenko (Washington University) for carrying out the Hepaticus
screening. TNFR1/p55/ mice were a gift of Dr. R. Levy (University
of Miami).For crossfostering, on the day of birth the mother was removed from
the birthing cage and placed in a clean cage with the crossfoster litter.
Pups were weaned between days 21 and 28.
Co-housing of female, 8-week-old RAG2/ or WT mice with TRUC
mice was at a ratio of 1:3 for 8 weeks. By 12 weeks of age, many TRUC
mice required euthanasia and were replaced with 8-week TRUC mice
for the duration of the co-housing.
For studies of the progeny of antibiotic-treated mice, pups were
weaned at day 21 and examined 6 weeks after weaning. There was
no exposure to antibiotics after weaning.
Histology
Colons were cleaned with PBS or HBSS prior to fixation followed by
routine paraffin embedding, sectioning, and staining with H&E.
Sections were examined and the degree of colitis scored by one of
the authors (J.N.G.), who was blinded to the genotype and experimen-
tal protocols used. Each of 4 histologic parameters were scored as ab-
sent (0), mild (1), moderate (2), or severe (3): mononuclear cell infiltra-
ton, polymorphonuclear cell infiltration, epithelial hyperplasia, and
epithelial injury (Neurath et al., 2002). Colons from DSS-treated mice
were scored on a scale of 0–4 based on % of colon involved by inflam-
mation, % of crypt loss, presence of lymphoid follicles, edema, ero-
sions, and density of inflammatory cells. The scores for the parameters
were summed for a total severity score.
Barrier Function Assay
Mice were sedated with ketamine and xylazine. Fluorescein-dextran
(MW 3000, Invitrogen, 0.6 mg/gram mouse weight) was delivered per
rectum using a 3.5 Fr catheter. Serum fluorescence was measured,
and preinjection fluorescence was used as the blank. n = 4–6 per
group.
Preparation of Samples for EM
Samples were prepared for Epon embedding as per standard proto-
cols. Blocks were sectioned and stained with toluidine blue for light mi-
croscopy. Thin sections were picked up on uncoated grids, stained
with saturated aqueous uranyl acetate and acetone followed by lead
citrate, then examined with a JEOL 1200 electron microscope.
Abs
Abs were obtained from BD PharMingen unless otherwise noted: a-
B220/CD45R (RA3-6B2), a-CD11c (HL3), a-CD11b (M1/70), a–MHC
class II (AF6-120.1 and 39-10-8), a -CD45 (30-F11), a-Gr-1 (eBioscien-
ces), a-F4/80 (BM8, eBiosciences), a-CD8 (53-6.7), a-CD49b (DX5), a-
CD4 (RM4-5), a-CD3 (DAKO # AO452), a-S100 (Dako Inc.), a-CD62L
(MEL-14), a-cytokeratin 5/8 (RCK102, Santa Cruz), a-TNFR1 (H-5,
Santa Cruz), and a-CD25 (PC61).
Immunohistochemistry
Immunostaining for T-bet was performed on paraffin-embedded tissue
sections as described (Dorfman et al., 2003). For double staining of
human colonic biopsies, sections were stained with T-bet and S100
(Dako Inc). T-bet staining was as above with a-S100 using an ABC
amplification kit (Vector Laboratories). For CD11c IHC, biotinylated
a-CD11c and an amplification protocol were used.
For IF staining of colonic leukocytes, sections were stained with a-
CD3 and biotin a-CD11c and amplification protocols were used. Sec-
tions were counterstained with DAPI (Sigma), viewed with an Olympus
B40 microscope, and digitally photographed. Composites were as-
sembled in Adobe Photoshop (Adobe Systems Inc.).
TUNEL staining on the designated paraffin-embedded tissues was
performed using the fluorescein in situ cell death detection kit (Roche).
Anticytokine Therapy
a-TNF-a (clone TN3-19.12), a hamster a-mouse TNF-a neutralizing
IgG1, and control Ab, hamster a-GST IgG, were generous gifts of
Dr. R. Schreiber. TN3-19.12 and control hamster IgG were purchasedCell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc. 43
from Leinco Technologies, Inc. TN3-19.12 or control were given intra-
peritoneally at a dose of 15 mg/gm mouse weight every 7 days for 4
weeks.
Colon Explant Culture
Explant cultures were carried out following a modification of described
procedures (Rakoff-Nahoum et al., 2004). Media were collected after
4 hr and centrifuged, and the supernatant was aliquoted and stored
at 80C.
Measurement of Cytokines
Cytokines were measured in culture supernatants utilizing SearchLight
high dynamic range (HDR) imaging and analysis. For TNF-a, the mouse
BD OptEIA ELISA kit was used. Total supernatant protein concentra-
tion was measured and used to calculate the cytokine concentration
in pg/mg.
Colonic Epithelial Cell Culture
Epithelial cell culture and TUNEL staining was performed as described
with the following modifications (Baumgart et al., 1998). After 6 days,
cells were harvested and stained with a-CD45, cytokeratin 5/8, and
TUNEL reagent to label the apoptotic cells. After event acquisition
using a LSRII, CD45 cytokeratin 5/8+ cells were gated and the % of
TUNEL cells was quantitated using FACSDiva software.
Isolation of Colonic DCs for Flow Cytometry and
Intracytoplasmic Cytokine Staining
Mononuclear cells were isolated from the colon as described with
modifications as noted (Camerini et al., 1993). Cell suspensions were
layered onto Percoll gradients, and the 30%/70% interface, enriched
for mononuclear cells, was harvested.
Methods for FC and intracytoplasmic cytokine staining of colonic
leukocytes are as described with modifications noted (Rigby et al.,
2005). Cells were stained with PE-conjugated Abs directed against
TNF-a and the appropriate PE-conjugated isotype controls in parallel.
For FC, samples were acquired using a Becton Dickinson LSRII and
data were analyzed using FACS Diva software. For colonic DCs, acqui-
sition gates were constructed such that an equal number of CD11c+
class II+ cells were collected from RAG2/ and TRUC samples. Cell
sorting was performed using a FACS Aria II at the BWH Center for
Neurological Diseases Cell Sorting Core Facility.
Bone Marrow DC Culture
BMDCs were generated as described with the following modification:
MACS bead depletion for class II, CD8, CD4, and B220 was employed
and cells were cultured in the presence of GM-CSF (Inaba et al., 1992).
Human Myeloid DCs
CD14+ cells were isolated from pooled human buffy coats and cultured
in GM-CSF and IL-4 as has been previously described (Sallusto and
Lanzavecchia, 1994).
ChIP and qPCR
20 3 106 DCs, harvested on day 6 and treated with LPS 100 ng/ml for
24–30 hr and IFNg 20 ng/ml, were used per IP. Cells were fixed for 30
min at room temperature (RT) for IP with the T-bet polyclonal Ab, 9856.
ChIPs were performed as described (Ansel et al., 2004). 1/20 vol of the
ChIP sample was used per qPCR rxn. qPCR products were submitted
to agarose gel electrophoresis using SyBR gold dye (Invitrogen) to ver-
ify amplification of products of the correct size. Primers sequences for
qPCR are available upon request. qPCR reactions were carried out in
an ABI Prism 7700 Sequencer Detector using SYBR green reagents.
Luciferase Assay
Constructs are as follows: 3 kb mouse TNF-a promoter luciferase con-
struct (generously provided by Dr. A. Goldfeld, Harvard University),
a constitutively active Ikkb mutant construct, a Renilla construct for44 Cell 131, 33–45, October 5, 2007 ª2007 Elsevier Inc.normalization of transfection efficiency, and full-length T-bet cDNA
construct, or control plasmid. Luciferase and Renilla activity were as-
sayed using the Dual-Luciferase Reporter Assay System (Promega)
and a Monolight 2010 luminometer.
Broad Spectrum Antibiotic Treatment of TRUC Colitis
Mice were treated as described (Fagarasan et al., 2002; Rakoff-
Nahoum et al., 2004). Alterations are as noted: ampicillin (1 g/l; Roche),
vancomycin (1 gm/l; Henry Schein, Inc. [Hospira, Inc.]), neomycin sul-
fate (1 g/l; Sigma), and metronidazole (1 g/l; Sigma) were dissolved in
autoclaved drinking water and fluid intake was monitored. Treatment
was for 6 weeks.
Bacterial Culture
Bacteria culture methods were performed as described (Rakoff-
Nahoum et al., 2004). After 48 hr for aerobes or 72 hr for anaerobes
at 37C, colonies were counted. Anaerobic cultures were grown in an-
aerobic chambers.
Adoptive Transfer Experiments
Peripheral LNs were harvested and cell suspension generated. Immu-
nodepletion of CD8+, CD11c+, B220+, Ter-119+, DX5+, class II+ popu-
lations was performed with MACS beads depletion. The enriched cell
population was stained with a-CD4 (clone RM4-5), anti-CD62L (clone
MEL-14), and anti-CD25 (clone PC61) and subjected to FACS. CD4+,
CD62L hi, and CD25+ and negative populations were collected and
resuspended in PBS, and 75,000 were injected per mouse. 1 3 106
CD4+CD62L+CD25 cells were injected per mouse as noted. For B
cell AT, splenic B cells were purified using MACS-positive selection
and 1 3 106 CD19+ resuspended in PBS were injected per mouse.
After 4 weeks, mice were sacrificed except for mice receiving the naive
T cells or B cells, which were sacrificed after 2 weeks due to morbidity.
PBS was used for sham injection (error bars denote SD).
Statistical Analysis
All experiments were repeated three times unless otherwise noted.
Statistical analysis was performed using the unpaired Student’s
t test. Error bars represent standard deviations.
Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cell.com/cgi/content/full/131/1/33/DC1/.
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